Supplementary Information
histidine-tagged thermostable x5 Fluc (pET16bx5), and the wild-type Photinus pyralis Fluc (pPW601L) were kindly donated by Drs. Laurence Tisi (Lumora LTD, Ely, Cambridgeshire, UK) and Peter White (Dstl, Porton Down, UK), respectively. Firstly, the WT gene was shuttled into pET16b by BamHI/ NcoI digestion and subcloning, and was sequenced. Sitedirected mutagenesis (SDM) was carried out according to manufacturer's protocol (Quikchange TM , Stratagene Corp., CA, USA) to introduce the mutation S284T into x5 Fluc.
Over-expression, protein purification by NiNTA chromatography, SDS-PAGE and protein assays were carried out as detailed previously. [1] Spectrofluorometry. Absorbance and fluorescence spectra were acquired in Thermo Flash (Thermo Fisher Scientific, MA, USA) by 1:10 dilution of free acids of luciferin (1), our analogue (6) and the Maki red analogue (5) in TEM buffer at pH 7.8 at room temperature. See
Supplementary Figure S2 legend for details. To measure pH dependence of fluorescence spectra compounds were diluted in TEM buffers prepared between pH 6-9.
In vitro characterisation of bioluminescence properties. In vitro data was obtained by saponifying the esters using Porcine Liver Esterase (PLE -Sigma Aldrich, MO, USA) for at least 15 min prior to the addition of luciferase, without isolation of the free acid. TEM buffer (100 mM Tris-acetate, 2 mM ethylenediaminetetraacetic acid (EDTA) and 10 mM magnesium sulfate (MgSO 4 )) was pH adjusted at room temperature (RT) with 1-10 M sodium hydroxide or 6-10 M acetic acid. Bioluminescence spectra were acquired using a Cary Eclipse spectrophotometer (Agilent Technologies, CA, USA) using PMT gains of 800-1000 V and emission slits of 20 nm and 100 ms gating. Signal averaging was carried out if required ( Figure 2 ) and spectra were corrected for variation in photomultiplier tube spectral sensitivity by calibrating with lucifer yellow (Sigma, MA, USA) and 2-[4-(Dimethylamino)styryl]-1-methylpyridinium iodide (ASP+) (Sigma, MA, USA) dyes, and using the known corrected spectra from Molecular Probes. Table 1 : To initiate bioluminescence, 50 µL of 0.1 mg/mL 1 or 1 mg/mL of 5 or 6
and 20 µL 20mM ATP was added to 20 µL 7µM solutions of Fluc in cold TEM buffer.
Specific activities of enzymes were calculated by integrating light emission from 1 mM substrates, 5 mM ATP and 0.5 µM Fluc in 100 uL TEM at room temperature and using no filter for 2 min in the Photon imager device (Biospace Labs, Paris, France). FWHM:
bioluminescence Full-width half-maximum. Details as in Table 2 . Error +/-2 nm. imager (Caliper, USA) and kinetic parameters were calculated using the Hanes-Woolf plot. [2] Specific activities of 1, 5 and 6 esters with purified enzymes: to capture specific activities of enzymes with substrates, 40 µL 0.5 µM x5 Fluc in 5 mM TEM buffered ATP was added to saponified esters and light emission was captured for 2s using the IVIS Imager.
Production of human retrovirus, transduction and maintenance of cell lines. Retroviral vector was generated by co-transfecting 293T cells with vector plasmid, along with RDF plasmid which supplied the RD114 envelope as described previously. [3] Cell lines were either purchased from ATCC, or provided by the UCL Cancer Institute cell bank. In vivo bioluminescence imaging and acquisition of in vivo bioluminescence spectra.
'Animal work was carried out in accordance with Home Office regulations and guidelines as set out by the 1986 Animals Act (Scientific Procedures). Prior to imaging, mice were anaesthetised using 4% isoflurane and 2 L/min oxygen and during imaging were maintained using using 1.5% isoflurane and 1 L/ min oxygen and prior to imaging mice were ip injected Bioluminescence spectra of native 1 (LH 2 ) and 6 (iLH 2 ). Bioluminescence spectra were acquired in a Photon Imager (Biospace Labs, Paris, France) which contains a sensitive intensified charge-coupled device (iCCD) detector with good red spectral sensitivity, by multiple consecutive 30s acquisitions using different band pass filters and correcting each output for overall signal decay. This enabled the determination of the proportion of light emitted at each wavelength for 1 (LH 2 ) and 6 (iLH 2 ) with different mutants. See Figure 4 legend (C) for details. Acquisition of spectra as in S4, but 15 s integration times used for both substrates.
General Experimental Details.
All manipulations were routinely carried out under an inert (Ar or N 2 ) atmosphere. All reagents were used as received unless stated. For the purposes of thin layer chromatography (tlc), Merck silica-aluminium plates were used, with uv light (254 nm) and potassium permanganate or anisaldehyde for visualisation. For column chromatography Merck Geduran ® Si 60 silica gel was used. Butyl lithium solutions were standardised with diphenyl acetic acid.
All NMR data was collected using a Bruker AMX 300 MHz, Bruker AVANCE 500 MHz or 6-Hydroxy-2-bromo-benzothiazole (S1) was synthesised in two steps from commercially available 6-methoxy-2-amino-benzothiazole using literature procedures. [4, 5] Amino acid, DTrtCysOMe [6] was synthesised using an analogous method to that developed for L-cysteine by Rudolph et al., and protected as the methyl ester using thionyl chloride. [7] Benzyl bromide was quenched with saturated NaHCO 3(aq) (2 mL) and taken up in EtOAc (10 mL), the aqueous layer was back extracted using EtOAc (2 × 5 mL), organics dried over MgSO 4 A solution of S10 or S11 in phosphate buffer (1 mg/mL) was treated with PLE (5 µg per 1 mg of ester) and incubated at 37 °C for 24 h. After this time the saponified ester 6 was used directly without isolation. 
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